Table 8 Univariate and multivariate analyses of the two groups
The Psoriasis group | The Control group | P | OR(95%CI) | P’ | |
|---|---|---|---|---|---|
Number, n | 18 | 72 | |||
Age (years) | 48(44-67) | 41(24-52) | 0.005 | 0.954(0.895-1.017) | 0.151 |
Sex, n(%) | 13(72) | 54 (75) | 0.809 | 3.405(0.207-56.081) | 0.391 |
Poor economic condition, n(%) | 6(33%) | 15(21) | 0.262 | 0.344(0.021-5.701) | 0.456 |
Family history, n(%) | 6(33%) | 9(13) | 0.034 | 0.007(0.000-4.174) | 0.128 |
Course of disease (month) | 120(45-240) | 72(6-120) | 0.026 | 0.996(0.984-1.009) | 0.556 |
AIS score | 6(0-11) | 1(0-9) | 0.048 | 0.995(0.729-1.358) | 0.977 |
PASI score | 39(31-49) | 29(18-37) | 0.011 | 0.904(0.845-0.968) | 0.004 |
DLQI score | 11(10-17) | 4(2-7) | 0.000 | 0.601(0.429-0.842) | 0.003 |
Dopamine (pg/ml) | 50.15(47.01-51.43) | 54.74(51.54-57.93) | 0.000 | 1.448(1.033-2.029) | 0.032 |
Norepinephrine (pg/ml) | 149.22(140.05-158.83) | 149.28(142.99-161.13) | 0.928 | 1.002(0.913-1.101) | 0.961 |
Epinephrine (pg/ml) | 29.84(29.12-31.53) | 31.78(29.17-34.30) | 0.155 | 0.952(0.787-1.151) | 0.611 |